Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ILK | Q13418 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7074398 | 0.93 | KDM4E (0.37) | KDM4EMAPTKMT2AGPR3EGFR | |
| SCHEMBL3021084 | 0.83 | KDM4E (0.35) | KDM4EMAPTGPR3EGFRPOLB | |
| SCHEMBL27991341 | 0.83 | TLR8 (0.49) | TLR7 | |
| SCHEMBL8501798 | 0.83 | KDM4E (0.37) | KDM4EMAPTKMT2AGPR3EGFR | |
| SCHEMBL4557233 | 0.81 | TLR8 (0.50) | TLR7 | |
| SCHEMBL28605200 | 0.81 | HRH1 (0.42) | KDM4EMAPTGPR3EGFRPDE10A | |
| SCHEMBL30336491 | 0.81 | TLR8 (0.50) | TLR7 | |
| SCHEMBL7069013 | 0.79 | TLR8 (0.49) | TLR7KDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL7548524 | 0.79 | KDM4E (0.37) | KDM4EMAPTGPR3EGFRALDH1A1 | |
| SCHEMBL6597830 | 0.78 | SORD (0.47) | KDM4EMAPTGPR3EGFRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | REDDY US THERAPEUTICS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | HPSE, ENGASE, UGCG | JAK2 1071/4885TLR7 3458/4885KDM4E 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.